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Abstract 
After several decades of uncovering the cancer features and following the improvement of 
therapeutic agents; however cancer remains as one of the major reasons of mortality. 
Chemotherapy is one of the main treatment options and has significantly improved the overall 
survival of cancer patients, but these agents are highly toxic for normal cells. Therefore, there 
is a great unmet medical need to develop new therapeutic principles and agents. Targeted-
based cancer therapy (TBCT) agents and methods have revolutionized the cancer treatment 
efficacy. Monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) are among the 
most effective agents of TBCT. These drugs have improved the prognosis and survival of 
cancer patients; however, the therapeutic resistance has subdued the effects. Several 
mechanisms lead to drug resistance such as mutations in the drug targets, activation of 
compensatory pathways and intrinsic or acquired resistance of cancer stem cells. Therefore, 
new modalities, improving current generation of inhibitors and mAbs as well as optimizing 
the combinational therapy regimens are necessary to decrease the current obstacles in front of 
TBCT. Moreover, the success of new TBCT agents such as mAbs, SMIs and 
immunomodulatory agents has sparked further therapeutic modalities with novel targets to 
inhibit. Due to the lack of cumulative information describing different agents and methods of 
TBCT, this review focuses on the most important agents and methods of TBCT that are 
currently under investigation.   
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Introduction 
Cancer is a complex invasive disorder and is one of the major reasons of a significant 
mortality rate worldwide. Cancer incidence is correlated with a combination of the interaction 
of oncogenes, tumor suppressor gene mutations and environmental forces [1].  
For several years, traditional chemotherapy has been the main treatment modality in cancer 
patients in addition to radiation therapy and surgery [2]. These agents and methods may lead 
to complete remission and be effective in reducing tumor size and metastasis. However, most 
chemotherapy agents kill dividing cancer and normal cells and have high incidence of life-
threatening complications [2]. On the other hand, resistance to chemotherapy presented a 
major obstacle to attempt to increase the prognosis of patients. Tumor cell resistance (intrinsic 
and acquired) results from the genetic and epigenetic modifications occurring in cancer cells 
before or after chemotherapy.  
Therefore, developing new therapeutic agents and methods that specifically kill tumor cells, 
spare normal cells and overcome drug resistance is imminent. 
 
Targeted-based cancer therapies (TBCT) have significantly improved and several specific 
agents and interesting approaches have been developed (Table 1) [3-8]. Moreover, the 
application of immunomodulatory (IMiDs) agents has tremendously improved the survival of 
cancer patients.  
Among several TBCT drugs, different types of inhibitors such as small molecule inhibitors 
(SMIs), monoclonal antibodies (mAbs) and antagonists have been described to control the 
progression of various cancers [5, 9, 10].   
Targeting tumor cells using mAbs and SMIs against receptor tyrosine kinases (RTKs) or 
intracellular kinases have been described in several review articles [5, 9, 11]. This review 
describes the most important agents and methods of TBCT and the recent advances in the 
field of targeted cancer therapy. 
Small molecule inhibitors (SMIs) 
SMIs are chemical substances that interrupt with molecules required for cells growth and 
function. These agents specifically target molecules with a unique construction that differs 
from traditional chemotherapy drugs. SMIs are used for the treatment of various diseases such 
as autoimmune and malignant disorders [5, 12].  
4 
 
Currently, several inhibitors are in clinical use or are under investigation in pre-clinical and 
clinical stages. SMIs of tyrosine kinases (tyrosine kinase inhibitors; TKIs) are one of the 
major groups.  
Afatinib, erlotinib, lapatinib, ibrutinib, and sunitinib are examples among the current 
approved TKIs for cancer treatment. Moreover, new SMIs targeting RTKs such as AXL and 
ROR1 are promising drugs that are in pre-clinical settings [5, 9, 13]. 
Recently, several new and interesting inhibitors have emerged and will be discussed in 
following sections. 
 
Inhibitors of pro-survival signaling pathways 
Several inhibitors have been developed to target the intracellular key proteins, in which most 
of them are dysregulated pro-survival or signaling molecules. Upregulation of pro-survival 
modulators as well as suppression of anti-apoptotic proteins are important for tumor cells 
survival. Targeting these molecules such as Bcl family members involved in cell survival 
signaling pathways are of great importance.  
 
Pro-survival inhibitors 
Navitoclax (ABT-263) is a Bcl-2/Bcl-XL/Bcl-w inhibitor that binds to Bcl-2 family proteins 
with higher affinity than other Bcl-2 inhibitors (100-1000 fold greater). Bcl-XL is highly 
expressed on platelets and navitoclax induced thrombocytopenia in treated patients [14]. 
Significant clinical benefit has been demonstrated in chronic lymphocytic leukemia (CLL) 
patients [15]. Navitoclax induced partial remission in one-third of relapsed CLL patients. Pre-
clinical and clinical studies have shown that navitoclax may enhance sensitivity of small cell 
lung cancer cells to standard cytotoxic agents [15, 16]. Moreover, combination of TKIs with 
pro-survival inhibitors, such as navitoclax might also sensitize tumor cells to treatment [17]. 
Navitoclax is under investigation in combination with mAbs (e.g. rituximab), TKIs (e.g. 
erlotinib) and other drugs in clinical trials. Leukemic cells in the bone marrow (BM) are less 
responsive to navitoclax due to the contact with stromal cells and upregulation of anti-
apoptotic proteins [18]. Therefore, combination of other agents that release leukemic cells 
from BM or lymph nodes might increase the efficiency of navitoclax. Combination of 
navitoclax and ibrutinib may be an appropriate strategy to target resident tumor cells in 
tissues. Treatment of CLL patients with ibrutinib increased the number of blood lymphocyte 
and resulted in lymphocytosis. A majority of these CLL cells released from lymph nodes 
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followed by rapid resolution of enlarged lymph nodes [19]. Released leukemic cells loss their 
contact with supporting stromal cells and become deprived of survival contacts [19].  
 
PARP inhibitors as part of DNA-repair machinery 
Poly ADP ribose polymerases (PARP) have been known as an important DNA repair enzyme 
group. These enzymes are present in the nucleus and are activated by DNA damage. Due to 
the crucial role of PARP enzymes, PARP inhibitors are potential and novel therapeutic drugs 
for cancer treatment.  
Several PARP inhibitors are under investigation as single agents or in combination with other 
DNA damaging drugs such as ionizing radiation. Currently, more than nine PARP inhibitors 
are in different stages of clinical settings for cancer treatment (Table 2).  
PARP inhibitors are more proper for the treatment of patients with mutated BRCA1/2 (breast 
cancer, early onset) genes associated cancer than others. These mutations cause mistakes in 
DNA repair machinery and are lethal for cells when the DNA repair protein, PARP1 is 
inhibited [20].  
Rucaparib (PF-01367338, AG-014699) is a PARP inhibitor, and pre-clinical studies have 
shown a better effect in combination with temozolomide [21]. In the first phase I trial, 
rucaparib combination with temozolomide was evaluated in 32 patients with different solid 
tumors [22]. Rucaparib combination with temozolomide showed PARP inhibition at all doses 
and in a dose escalation evaluation, PARP inhibitory dose was determined to be 12 mg/m
2
 
with a constant dose of temozolomide at 100 mg/m
2
/day. The maximal tolerated dose for the 
combination was 12 mg/m
2
 for rucaparib and 200 mg/m
2
/day for temozolomide. Mean of 
PARP inhibition at 5 hours was determined to be 92%, ranged from 46% to 97% and DNA 
single-strand breaks was noted for all treated patients. No major side effect was observed for 
rucaparib alone and no interaction with temozolomide was noted [22].  
In a phase II study of the rucaparib, the combination with temozolomide in patients with 
metastatic melanoma was studied [23]. In this study, patients with no prior chemotherapy 
were evaluated. Treatment was given until disease progression. The response rate, median 
time to progression and median overall survival were 17.4 %, 3.5 and 9.9 months, 
respectively. Myelosuppression was described in 54% of patients [23].  
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Olaparib or AZD-2281 is an inhibitor of PARP1/2 with peak plasma concentration between 1-
3 hours and half-life of 5-7 hours. In the first-in-human phase I trial the maximal tolerated 
dose was established as 400 mg/2 days [24]. Overall response rate and disease control rate 
were shown to be 47% and 63%, respectively in 19 ovarian breast, or prostate patients with 
BRCA gene mutations [24]. In several clinical trials olaparib has shown clinical benefits with 
anti-tumor activity in BRCA1 and 2- deficient breast and ovarian cancer patients [24].  
Veliparib (ABT-888), iniparib (BSI-201), CEP-9722, E7016 (GPI-21016), INO-1001, and 
LT-673 (BMN-673) are other potent PARP inhibitors that are under investigation in clinical 
trials as single agent or in combination therapy. 
 
HDAC inhibitors 
Normal cellular functions such as cell cycle arrest at different stages and apoptosis are mostly 
regulated by histone proteins that are modulated by protein acetylation [25]. Deregulation of 
histones acetylation have been shown to be related with aggressive disease and poorer 
response to the current treatments [26]. The acetylation states of proteins are modified by the 
opposing effects of histone acetyl-transferases (HATs) and histone deacetylases (HDACs) 
[27].  
HDACs are categorized into several classes based on homology to yeast HDACs and their 
dependence to Zinc. These groups are class I (HDACs 1-3 and 8) (also named true HDACs), 
class II a/b (HDACs 4-7,9 and 10) and class IV (HDAC 11) [25]. In contrast to HDAC class I 
members that are located in nucleus, class II HDACs are located in cytoplasm, but can 
translocate into the nucleus. Class III HDACs [sirtuin enzymes (SIRT 1–7)] are independent 
of Zinc for function. Moreover, HDAC classes have different histone substrates. Histone is 
the main substrate of class I while both histone and non-histone proteins are class II HDACs 
substrates, and conversely, non-histone proteins act as class III HDACs substrates [25]. 
Moreover, based on the chemical structure, HDACs inhibitors are classified into several 
groups. These groups are hydroxamic acids (trichostatin A), carboxylic acids (valproate), 
aminobenzamides (entinostat), cyclic peptides (apicidin), epoxyketones (trapoxins), and 
hybrid molecules [28].  
Protein acetylation and deacetylation are dysregulated in several tumors, including breast, 
ovarian, pancreatic cancers, multiple myeloma, T-cell lymphoma (TCL), cutaneous T-cell 
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lymphoma (CTCL), melanoma, neuroendocrine tumors, leukemias, and Hodgkin lymphoma 
[26]. HDACs inhibitors induce apoptosis, senescence, differentiation, and inhibit tumor cells 
angiogenesis and growth; however they have no major effects on normal cells.  
 
Clinical evidences demonstrated that HDACs inhibitors have promising anti-tumor effects. 
Vorinostat (Zolinza), panobinostat (LBH-589), belinostat (PXD-101), entinostat (MS-275 or 
SNDX-275), mocetinostat (MGCD0103), and romidepsin (Istodax) are promising HDACs 
inhibitors and target different members of HDACs [25].  
Vorinostat and romidepsin have been approved by the FDA for the treatment of patients with 
refractory CTCL [28]. Vorinostat was the first HDACs inhibitor approved by the FDA for the 
treatment of progressive CTCL on October 6, 2006 (Table 2) [29]. Phase II clinical trials for 
evaluation of romidepsin were started in 1997 on various malignancies and promising results 
were found in the treatment of CTCL and other peripheral T-cell lymphomas. On November 
5, 2009, the FDA approved romidepsin for the treatment of CTCL [30]. 
Currently, new generation of HDACs inhibitors have been developed and some of them have 
entered the clinical trials, including CHR-3966, chidamide [31], AR-42, hydroxamides 
quisinostat, and abexinostat [28, 32]. Pre-clinical studies indicated these inhibitors are more 
potent than the parental agents, with proper pharmacodynamic, pharmacokinetic and lower 
side effects.  
 
MTOR inhibitors 
MTOR (mammalian target of rapamycin), also recognized as FK506 binding protein 12-
rapamycin associated protein 1 (FRAP1) belongs to the phosphatidylinositide 3-kinases 
(PI3K) protein family. MTOR is an intracellular serine-threonine kinase that collects the 
growth and survival signals received by tumor cells as a central kinase. It is activated in tumor 
cells by different mechanisms such as RTKs stimulation, oncogenes and loss of tumor 
suppressor genes [33].  
Different mTOR inhibitors such as deforolimus, everolimus and temsirolimus have been 
approved for cancer treatment and several other inhibitors are in pre-clinical and clinical 
stages (Table 2).  
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Deforolimus (ridaforolimus, AP23573 or MK-8669) is an analog of rapamycin. MTOR 
blocking by deforolimus induced a starvation effect in tumor cells by interfering with cell 
growth, cell division, metabolism, and angiogenesis [34]. Everolimus in combination with 
tamoxifen, letrozole, or exemestane has shown high clinical efficacy for the treatment of ER
+
 
metastatic breast cancer patients [35]. This inhibitor was approved by the FDA for the 
treatment of advanced recurrent colorectal carcinoma after failure of the treatment with 
sunitinib or sorafenib [36]. On August 29, 2012, the FDA granted accelerated approval for 
everolimus for the treatment of patients with tuberous sclerosis complex who have 
subependymal giant cell astrocytoma (SEGA). Everolimus is the first pediatric inhibitor drug 
to be approved by the FDA for the treatment of tumors that occur primarily during childhood 
[37]. 
Temsirolimus (Torisel) is a derivative of sirolimus and was approved by the FDA and the 
European Medicines Agency (EMA) in May and November 2007, respectively for the 
treatment of patients with recurrent colorectal carcinoma [38]. It interferes with protein 
synthesis and controls tumor cells proliferation, growth and survival. Temsirolimus has been 
shown to induce cell cycle arrest in the G1 phase and prevented tumor angiogenesis by 
inhibiting VEGF synthesis [39]. 
It has been shown that the PI3K/Akt/mTOR pathway is used by ER
+
/HER2
+
 tumors to escape 
control of anti-ER and HER2 therapies, including, specific mAbs and SMIs. The combination 
of mTOR inhibitors with current ER/HER2-targeted therapies may be a promising approach 
for overcoming and preventing the development of drug resistance [40]. 
 
Targeting RNA translation in tumor cells  
Several molecules involved in the process of RNA translation and protein synthesis are proper 
targets for special type of inhibitors that react with nucleic acids. RNA targeting is a 
developing approach to anti-tumor therapeutics that requires identification of specific 
inhibitors to target different RNA structures. Specific structures in RNA form several types of 
secondary structures like hairpin loops, internal loops, and bulged regions that are proper for 
the binding of inhibitors [6, 41].  
Pre-mRNA splicing is an essential step in gene expression and the maintenance of high-
fidelity of this process is vital to allow correct protein expression [42]. MRNA splicing is 
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usually disrupted in cancer that might be due to altered expression of RNA-binding proteins, 
involved in mRNA splicing and results in changes in normal process of alternatively spliced 
mRNAs [43]. Inhibitors or regulators that block or modify the splicing process of pre-mRNA 
might be proper for therapeutic applications. Currently, a few inhibitors are available with 
which to dissect the splicing process. Therefore, the identification of selective inhibitors that 
either prevent or change, pre-mRNA splicing would be valuable for therapeutic applications 
[43]. 
Polyamines are poly-cationic amines that play important roles in sustaining cellular growth 
and activities. In cancer cells, their concentration is high and decrease in concentration 
inhibits cellular growth and induces apoptosis [41]. Polyamines and analogues (e.g. 1-
naphthylacetyl spermine, NASPM) have been shown to interact and stabilize DNA and RNA. 
Some analogues have demonstrated strong activity against tumor growth in different types of 
cell lines [44]. Polyamine analogues do not substitute for the natural polyamines involved in 
normal cell function, therefore, they show selective anti-tumor activity [45]. Hence, 
polyamines are essential for cancer cells proliferation and targeting these agents is a proper 
strategy. 
Moreover, several natural compounds, and their synthetic derivatives were described to 
prevent splicing. GEX1A, FR901464, E7107, pladienolide B, pladienolide D, sudemycin, and 
spliceostatin A (SSA) are examples of these compounds that target the SF3b subunit of the 
U2snRNP [43]. 
Madrasin is one of the mRNA splicing modulators that was reported by Pawellek et al. [43]. 
This inhibitor interfered with the early stages of spliceosome assembly and interrupts its 
assembly at the complex A. Madrasin is cytotoxic at high concentrations, while at low 
concentrations it induces cell cycle arrest, stimulates reorganization of sub-nuclear protein 
localization and controls splicing of several types of mRNAs [43]. 
Sudemycins (FR901464), an inhibitor of splicing showed cytotoxic activity against tumor 
cells both in vivo and in vitro in xenograft models through targeting SF3b factor [46]. 
Pladienolide is a naturally occurring anti-tumor macrolide that inhibits the process of mRNA 
splicing. Pladienolide binds directly to spliceosome-associated protein 155 (SAP155, SF3b 
subunit 1) and the inhibitory activity is dose-dependent. Data suggested that SF3b factor is a 
potential anti-tumor drug target [47].  
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E7107 that targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b is a 
derivative of the pladienolide family. This product is in clinical trial and promising results 
have been achieved [48, 49]. 
Other synthetic or natural inhibitors of mRNA splicing are under investigation in pre-clinical 
and clinical evaluation. 
 
Targeting tumor cells by microRNAs 
MicroRNAs (miRNAs or miR) are a type of non-coding small RNA molecules (21-25 
nucleotides in length), which control gene expression. Several function, including regulation 
of gene expression, tumor cells resistance to treatments and behave as tumor suppressor genes 
have been described [50]. Dysregulation of miRNAs can be associated with several diseases 
and is involved in a variety of pathophysiologies due to aberrant expression [51, 52].  
MiRNAs are involved in tumor cells sensitivity to treatments. It has been shown that miR-7 
sensitized NSCLC cancer cells to paclitaxel [53]. Overexpression of miR-7 increased the 
sensitivity of NSCLC cells to paclitaxel by suppressing cell proliferation and induced cell 
apoptosis, while the inhibition of miR-7 disrupted the anti-proliferative and pro-apoptotic 
effects of paclitaxel. MiRNA such as miR-203 have been shown to downregulate TLR4 and 
the downstream cytokines in dendritic cells [51]. MiR-30e promoted apoptosis of acute 
myeloid leukemia (AML) cells to imatinib treatment through regulation of the oncogenic 
BCR-ABL protein. MiRNA-105 has been demonstrated to inhibit cell proliferation and 
repressed PI3K/Akt signaling pathway in hepatocellular carcinoma [54].  
Overexpression of miR-548l inhibited NSCLC cell migration and invasion. MiR-548l can 
bind to Akt1 and overexpression of Akt1 inverse the effects of miR-548l in NSCLC cells. It is 
indicated that Akt1 is involved in the effects of miR-548l and suppresses the migration and 
invasion of NSCLC cells [55]. 
Conversely, some miRNAs are involved in tumor cells resistance to different therapeutic 
agents. Overexpression of miR-1, miR-125a, miR-150, and miR-425 in glioblastoma 
increased the resistance of tumor cells to radiotherapy via upregulation of the cell cycle 
checkpoint response. Antagonists of these miRNAs sensitized glioblastoma cells to 
irradiation, suggesting their potential as targets for preventing therapeutic resistance [56]. 
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Monoclonal antibodies: the most specific tools for targeted cancer therapy 
Extracellular molecules such as cell surface receptors or soluble proteins are the conventional 
targets for mAbs. Several cluster of differentiation (CD) markers such as CD20, CD23, CD33, 
CD40, CD52, CD74, CD152 [cytotoxic T lymphocyte antigen-4 (CTLA-4)], CD279 
[programmed death-1 (PD-1)], and CD274 [programmed death-ligand 1 (PD-L1)] are 
appropriate targets, which are under investigation for TBCT by mAbs (Table 3). MAbs 
against these molecules destroy tumor cells by different mechanisms such as complement-
dependent cytotoxicity (CDC), antibody-dependent cell mediated lysis (ADCC) and induction 
of direct apoptosis or necrosis [57-59]. MAbs targeting RTKs and several CD markers have 
been described in several articles and will not be discussed here; however, anti-CD20, anti-
CD52, anti-CD152, anti-CD279, and anti-CD274 mAbs are described briefly as interesting 
tools for targeted cancer therapy.   
 
Anti-CD20 mAb 
CD20 is a signature B-cell differentiation marker and is an activated-glycosylated 
phosphoprotein expressed on all B cells beginning at the pro-B stage (CD45R
+
, CD117
+
) with 
increased expression on mature B cells [60]. This antigen is expressed in several 
malignancies, including CLL, B-cell lymphomas, hairy cell leukemia, Hodgkins disease, 
melanoma cancer stem cells, myeloma, and thymoma [61]. 
Currently, there are two types of anti-CD20 mAbs that were approved for the treatment of B-
cell malignancies [62]. Rituximab (Rituxan) is a chimeric type I anti-CD20 mAb. This 
antibody is used as single agent or  combination therapy in relapsed or refractory indolent-non 
Hodgkins lymphoma (NHL) [63] and CLL patients [64]. Rituximab exerts its cytotoxicity 
through CDC, ADCC and week direct apoptosis [65]. This antibody has become part of 
standard chemoimmunotherapy [(fludarabine, cyclophosphamide and rituximab (FCR)] for 
most of untreated CLL patients [66].  
Ofatumumab (Arzerra) was the second anti-CD20 mAb developed after rituximab for cancer 
treatment. It is a humanized type I anti-CD20 mAb targeting a different epitope on CD20 than 
the one targeted by rituximab and demonstrated higher activity in CDC and ADCC compared 
to rituximab, in vitro [62]. It was approved on October 20, 2011, for the treatment of CLL 
patients who are refractory to alemtuzumab and fludarabine treatment [65, 67, 68]. Recently, 
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(April 17, 2014) the FDA approved this mAbs as single agent therapy for the treatment of 
CLL patients with no prior treatment or for those who are not eligible for chemotherapy 
(fludarabine-based therapy).  
Obinutuzumab (Gazyva) is a novel, third generation fully humanized anti-CD20 mAb (type 
II). The Fc-region of obinutuzumab is glycol-engineered to result in higher affinity binding to 
the CD20 [69]. The mechanism of action of obinutuzumab is CDC and ADCC. 
Obinutuzumab showed an elevated ADCC as well as a markedly higher induction of direct 
cell death in vitro, compared to rituximab [186]. This mAb is able to elicit actin-dependent, 
lysosomal cell necrosis in CLL cells in vitro [187]. Obinutuzumab was approved by the FDA 
on November 1, 2013, for the treatment of CLL in combination with chemotherapy in 
previously untreated patients [70].  
Currently, other anti-CD20 mAbs are in pre-clinical and clinical trials development. 
 
Anti-CD52 mAb (Alemtuzumab) 
Alemtuzumab is a humanized anti-CD52 mAb for the treatment of B-cell malignancies [71]. 
This mAb was approved on May 7, 2001 for the treatment of refractory CLL patients [72, 73].  
The mechanism of action is mostly through ADCC and CDC [74, 75]. Alemtuzumab has 
serious side effects due to the widespread expression of CD52, including prolonged 
lymphopenia with an increased risk of infections [76]. About 20% of CLL patients have been 
shown to have cytomegalovirus (CMV) reactivation usually occurs after 3–8 weeks of 
alemtuzumab treatment [77]. This antibody has also been tested with limited success in the 
treatment of NHL and for the preparation of patients with blood malignancies for BM 
transplantation. There are also clinical trials ongoing to test the ability of this antibody to 
prevent tissue rejection in transplantation [78, 79]. 
 
Anti-CTLA-4, PD-1/PD-L1 mAbs 
These molecules are involved in suppressing the immune system during different situations 
such as cancer. Targeting CTLA-4, PD-1/ PD-L1 antigens with mAbs has shown promising 
therapeutic results in several malignancies [80].  
Several mAbs have been produced against these antigens, which are in preclinical and clinical 
settings for the treatment of various tumors, however; ipilimumab (anti-CTLA-4) and 
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pembrolizumab (anti-PD-1) (Table 3) have been approved for the treatment of advanced 
melanoma on March 25, 2011 and September 4, 2014, respectively [80].  
Ipilimumab is a fully human mAb that prevents CTLA-4 engagement and induce the 
activation of anti-tumor T-cell immune responses. Targeting CTLA-4 is currently the main 
immunotherapeutic approach that has shown significant clinical benefit in melanoma patients 
[81].   
Pembrolizumab is a blocking humanized mAb (IgG4) that binds to the PD-1 and inhibits its 
interaction with PD-L1 and PD-L2, leading to the activation of immune response.  
Currently these two mAbs are under clinical investigation for the treatment of several 
malignancies, including NSCLC, small cell lung cancer (SCLC), prostate, bladder, and 
metastatic hormone-refractory cancers [82-84]. 
 
There are other approved mAbs which are using as the first- or second-line of cancer 
treatment, including CD74 (milatuzumab), CD40 (dacetuzumab), CEA (labetuzumab), and 
CD23 (lumiliximab) molecules (Table 3). Moreover, several other humanized mAbs are in 
various stages of clinical testing but not yet approved by the authorities to be used for therapy.  
 
Targeting EMT in cancer 
The epithelial to mesenchymal transition (EMT) is involved in many processes, including 
tissue and organogenesis as well as metastatic spread of cancer cells. Targeting this 
phenomenon by preventing the transition of epithelial to mesenchymal cells might be a proper 
strategy. EMT is classified into 3 types. Type 1 EMT is the process of embryogenesis during 
the embryo development, type 2 refers to the normal process of wound healing and the 
process of cancer metastasis is classified as type 3. Loss of epithelial cell to cell junctions and 
apical-basal polarity are the major hallmarks of these three types [85]. 
Different intermediates such as transcription factors are responsible for EMT transition. The 
main regulators of EMT transition are transcription factors that are classified into 3 families, 
including zinc-finger E-box-binding (ZEB), TWIST and SNAIL. SNAIL2, ZEB1, ZEB2, 
E47, KLF8, TWIST1, and FOXC2 transcription factors promote EMT in various cancer cells 
[86, 87].  
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The basic feature of EMT is the suppression of E-cadherin expression that is responsible for 
sustaining the cells junctions and cell-cell adhesion. SNAIL, TWIST and ZEB expression can 
suppress E-cadherin and activating critical mesenchymal genes, including N-cadherin, 
vimentin and fibronectin. These transcription factors regulates and activates the expression of 
mesenchymal genes while inhibiting epithelial genes expression [85]. 
Several mechanisms have been suggested to target EMT process for TBCT. These EMT 
targets are transcriptional regulators such as SNAIL, mediators (e.g. TGFβ), non-coding 
RNAs, and cancer stem cells (CSCs). Moreover, targeting the tumor microenvironment 
interactions, the role in initiation and termination of EMT might be considered [85].  
 
Various inhibitors, including CX-4945, EW-7195, EW-7197, IN-1130, SB-431542, SD-208, 
SD-093, LY580276, LY-573636, and LY2152799 are among EMT inhibitors [88]. These 
drugs target ALK5 (or TGFβ type 1 receptor) kinase. Ligation of TGFβ receptors (type 1 and 
2) by TGFβ will ultimately activate Smad proteins and their translocation to the nucleus. In 
the nucleus, Smad proteins regulate the expression of target genes including those involved in 
EMT, therefore, blocking ALK5 by theses inhibitors has demonstrated promises in inhibiting 
EMT [89]. 
 
Immune modulatory (IMiD) agents and targeted therapy 
It has been shown that several types of chemotherapy agents have side effects on immune 
cells. Therefore, a special class of therapeutic agents called immunomodulatory (IMiDs) 
agents was developed to be used in combination with chemotherapy or other targeted 
therapies to prevent immune system suppression. Later on, several groups showed that some 
of these drugs have not only immunomodulatory effects, but also can directly kill tumor cells.  
Currently, a few IMiDs agents have been approved by the FDA for the treatment of B-cell 
malignancies and several others are in pre-clinical or clinical settings. Lenalidomide and 
ibrutinib belong to this group [90].  
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Lenalidomide 
Lenalidomide or revlimid is a derivative of thalidomide and has several mechanisms of 
action. The anti-tumor and immunomodulatory effects are mediated through regulating innate 
and specific immune responses. For instance, it changed the immunological profile of the 
tumor cells microenvironment by preventing the secretion of pro-survival cytokines such as 
TNFα, IL-1β and IL-6, while favoring that of IL-2, IL-10, IL-12, and interferon γ (IFNγ) [91]. 
Moreover, it activated T and NK cells, inhibited tumor angiogenesis [92-94], changed the 
balance of Th1/Th2 cell toward Th1, increased the expression of CD80, CD86, HLA-DR, and 
stimulated the cytotoxic effects of T lymphocytes and natural killer cells [95]. 
Lenalidomide is mostly administrated for the treatment of patients with relapsed or refractory 
CLL [96, 97], multiple myeloma [98], MCL [99], and a few other lymphomas [91, 100]. The 
mechanism of action of lenalidomide exerts direct cell cycle arresting and pro-apoptotic 
effects on cancer cells, interrupts with physical and functional communication with the tumor 
microenvironment and mediates immunostimulatory activity. The cell cycle arrest and the 
consequent anti-tumor effects of lenalidomide are through the upregulation of cyclin-
dependent kinase inhibitors (CDKNs) [101].  
Lenalidomide inhibited the immunosuppressive effects of myeloid-derived suppressor cells 
(MDSCs) and regulatory T cells by preventing the expression of the transcription factor 
Forkhead box P3 (FOXP3). Indeed, this IMiD has shown robust anti-neoplastic effects in 
multiple myeloma patients previously subjected to stem cell transplantation while stimulating 
a transient increase in CD4
+
FOXP3
+
 Tregs [102].  
 
Ibrutinib 
Ibrutinib (Imbruvica) is an inhibitor of Bruton tyrosine kinase (Btk) that was reported in 2007 
[103]. This inhibitor was developed from the PCI-29732 inhibitor [103]. It binds covalently 
with cysteine (Cys) 481 in the ATP-binding pocket of Btk.  
Ibrutinib binds to the non-phosphorylated Btk and stabilizes this inactive conformation by 
internalizing Tyr 551 and prevents its phosphorylation. Ibrutinib inhibits other kinases, 
including Blk, Bmx, EGFR, Itk, and JAK3 [104]. These kinases have a cysteine residue in the 
homologous location to Btk. Ibrutinib has shown to be 1000-fold more selective for inhibition 
of BCR signaling in B cells over TCR signaling in T cells [104, 105].  
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Currently, several trials are assessing ibrutinib in malignant disorders, including CLL, 
DLBCL and Waldenström's macroglobulinemia, alone or in combination with other drugs 
[106].  
Recent studies have showed that ibrutinib blocked IL-2 inducible tyrosine kinase (Itk) in T 
cells. Th1 cells; however, express another kinase called resting lymphocyte kinase (Rlk or 
Txk). Following ibrutinib treatment, Itk in Th cells is inhibited and only Th1 cells survived 
due to the activation of Rlk survival pathway [107]. This event changes the balance of 
Th1/Th2 toward Th1 cells that are the main cells activating immune cells against tumor cells, 
intracellular pathogens and preventes the production of autoreactive antibodies [107].  
 
Targeting post-translational modification of proteins 
Post-translational modification (PTM) of proteins by glycosylation, phosphorylation, 
acetylation, ubiquitination, and other modifications is essential in moderating protein 
function. Aberrant PTMs underlie a majority of human diseases, including cancer and now it 
is well established that altered modifications vary significantly for cancer cells compared to 
normal counterparts and each type of tumor might have a unique PTM signature [108]. 
Current development of analytical techniques and instrumentation, especially in mass 
spectrometry has made it possible to recognize the type of protein PTMs in normal and cancer 
cells [109]. However, there are several issues that have not been solved such as determining 
the exact PMTs in tumor cells, mainly due to the intraclonal diversity of tumor cells within a 
population.  
Generation of mAbs that target PTMs might be of high interest. However, due to the low 
immunogenicity of non-protein molecules, production of effective mAbs against the above-
mentioned molecules is a major challenge. Moreover, for production of therapeutic mAbs, 
more information regarding PTMs in the protein of interest might be necessary.  
It has been shown that IgM anti-ganglioside antibodies induced by melanoma cell vaccine 
correlated with survival of melanoma patients [110, 111]. Numerous anti-disialoganglioside 
mAbs have also been developed for clinical use and have been trialed in metastatic 
melanoma. Disialoganglioside GD2 is overexpressed on the surface of tumors of 
neuroectodermal origin  and is an interesting target for mAbs [112]. 
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Targeting PTMs is in early stages and moreover, it is a challenging field and further 
investigations are warranted.  
 
Inhibition of Autophagy 
Autophagy process was first described by Porter KR et al. [113]. Autophagy is a catabolic 
activity involving the degradation of cell components through the lysosomal machinery. 
Several enzymes, including 30 autophagy-associated molecules (Atg) and 50 hydrolases 
within the lysosomes are involved in autophagy [114]. Cells use autophagy for the 
maintenance of cellular metabolism under starvation condition and to remove injured 
organelles under stress. This process is essential for normal growth control and is defective in 
several tumors as indicated as a pro-survival process in progressive tumor cells, leading to 
cancer resistance [115, 116].  
Several pre-clinical and clinical trials are ongoing to develop therapeutic drugs to inhibit 
autophagy. Different inhibitors of autophagy are classified as early- or late-stage inhibitors. 
Inhibitors such as 3-Methyladenine (3-MA), wortmannin and LY294002 target the Vps34 
(class III PI3K) and have been categorized as early-stage and chloroquine (CQ), HCQ, 
bafilomycin A1, and monensin that prevent the lysosomal function are classified as late-stage 
inhibitors [117]. Microtubule disrupting drugs like taxanes, nocodazole, colchicine, and vinca 
are defined as a separate class of autophagy inhibitors. CQ, HCQ and quinacrine are testing in 
clinical trials as promising anti-autophagy inhibitors.  
Moreover, it is known that autophagy process happens in minor population of tumor cells and 
these inhibitors may have better effects in combination with other anti-cancer agents. Indeed, 
most clinical trials have used HCQ in combination with other inhibitors. Autophagy inhibition 
can also improve the anti-tumor immune responses. Immunotherapeutic methods such as 
dendritic cell (DC) vaccines, adoptive transfer of T cells and administration of mAbs or 
cytokines are effective after the inhibition of the autophagic process [118].  
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Targeting the hypoxia induction 
Hypoxia is a main feature of solid tumors,  inducing an aggressive phenotype of tumors that is 
more resistant to therapies [119]. This process activates several pathways, including the 
hypoxia inducible factor (HIF), which mediates the effects of hypoxia in tumor tissues. 
Therefore, targeting the hypoxia by different inhibitors might be a proper treatment strategy 
[120].  
HIF-1 inhibitors have been shown to decrease tumor cells proliferation, increase necrosis and 
apoptosis of the cells and reduce tumor cell resistance to conventional therapies [121]. 
As HIF-1 is part of a transcriptional complex, special strategies are necessary to target 
hypoxia by inhibiting the HIF-1. Antisense strategies have been shown to decrease the 
expression of HIF-1a [122] and using a dominant-negative HIF-1a has been shown to 
decrease tumorigenicity of cancer cells by inhibiting glucose metabolism [123, 124].  
Targeting protein–protein interactions by inhibiting HIF-1a is another approach to block the 
activity of HIF-1 [125]. For example, HIF-1a requires the transcriptional coactivator 
p300/CBP. Chetomin is an inhibitor of HIF-1 that prevented its binding to p300. It has been 
shown that chetomin disrupted the structure of the CH1 domain of p300 and inhibited its 
interaction with HIF. Moreover, systemic administration of chetomin blocked hypoxia-
inducible transcription within tumors and inhibited tumor cell growth [126]. 
EZN-2968 is an antisense (16 nucleotide residues) of HIF-1a mRNA and reduces HIF-1a 
protein synthesis. In vitro studies showed that EZN-2968 inhibited tumor cell growth and 
downregulated HIF-1a-regulated genes. Furthermore, in vivo studies demonstrated decreased 
expression of HIF-1a mRNA in the livers of mice and anti-tumor activity in xenograft models 
of human prostate cancer [127]. EZN-2968 is under evaluation in patients with advanced solid 
tumors and potential effects were observed in metastatic renal cell carcinoma and 
hepatocellular carcinoma [128]. Several other agents such as Echinomycin (DNA intercalator) 
are under investigation in pre-clinical and clinical trials. 
Hypoxic media might be used against tumor cells using prodrugs that will be activated in 
these situations. Tumor cell death has been known to increase by the use of bioreductive 
prodrugs from several years ago [129, 130]. These prodrugs are activated under reductive 
conditions that are found within the tumor hypoxic environments. In most situations, it 
interferes with DNA replication and lead to cell death [35]. The ability for these prodrugs to 
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increase the killing effects of both irradiation and chemotherapy make them potential agents 
in the treatment of solid tumors [131]. Several prodrugs have shown promising results in 
combination with radiotherapy [132]. 
Inducible nitric oxide synthase enzyme (iNOS) catalyzes and activates prodrugs under 
hypoxic situations and produces nitric oxide (NO). NO is also synthesized by other nitric 
oxide synthase enzyme [132]. NO that is released by donor drugs increased radio-sensitivity 
of human tumor cells in hypoxic conditions in vitro and mimics the effect of O2 by fixation of 
radiation-induced DNA damage. Several studies have shown that NO has high anti-tumor 
activity in high concentrations. Therefore, these prodrugs can overcome radio-resistant tumors 
[133]. Some of these prodrugs will be activated in the hypoxic microenvironment of the 
tumors (bioreductive pro-dugs) [132].  
 
Induce tumor cells differentiation   
Differentiated cells have low or no proliferative and metastasis activities. The approach of 
differentiation therapy of cancer has been introduced many years ago. Several encouraging in 
vitro and in vivo results have been obtained; however, the only successful clinical application 
has been all-trans-retinoic acid (ATRA)-based therapy of acute promyelocytic leukemia 
(APL) [134]. Pathogenesis of APL is related with a chromosomal translocation that disrupted 
retinoic acid receptor a (RARα) gene located on the short arm of chromosome17 (q21) and 
resulted in an arrest of the early stage of promyelocyte differentiation. ATRA induces 
differentiation of APL blast cells [134].  
This approach is useful for targeting CSCs by using compounds that induce the differentiation 
of these cells, and therefore make them sensitive to other therapies. The main characteristic of 
CSCs is self-renewing and the capacity to differentiate to several cell populations. By 
inducing CSCs differentiation, cells will become more susceptible to anti-tumor therapy, and 
lose their ability to rebuild the tumor later. As described 37 years ago, retinoic acid (RA) is an 
appropriate molecule that induces cellular differentiation in embryonal carcinoma cell lines 
[135] through the upregulation of genes that promotes differentiation, like α-fetoprotein [136, 
137] and downregulation of pluripotency-associated ones like Oct4 or telomerase [138].  
Retinoic acid induces cell cycle arrest at the G1 stage through the downregulation of cyclin 
D1 by promoting protein degradation and suppressing mRNA synthesis as well as reduction 
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of the phosphorylation of retinoblastoma (Rb) protein [139]. RA has been demonstrated to 
induce cellular differentiation of keratinocytes, teratocarcinoma cells and APL, melanoma, 
and neuroblastoma cells in vitro [140-142]. Clinical studies have demonstrated some success, 
by combination of RA with other treatment protocols to overcome retinoid resistance [143]. 
In vitro studies have shown that combination of RA with HDAC inhibitors restores the 
expression of RARβ2 by renal cancer cells in xenografts, followed by inhibition of tumor 
growth [144] as well as in breast and thyroid cancers [145, 146]. Combination of RA and 
HDACs inhibitors has therapeutic effects in leukemia patients [147].  
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Conclusions  
Current data have demonstrated the high efficiency of TBCT agents and methods. Even the 
data are encouraging, however resistance to new agents, the plasticity of cancer cells, 
mutations, crosstalks between intracellular survival pathways and with the microenvironment, 
upregulation of other oncogenes, the tumor heterogeneity and cancer stem cell resistance are 
of the most important obstacles in front of researchers. Therefore, new applications such as 
appropriate drug combinations, new generation of mAbs and different methods of TBCT may 
be necessary. Moreover, specific targeting of cancer stem cells might be important to prevent 
tumor cell resistance to current TBCT methods; however, more investigation on CSCs 
phenotype, function and homing places for each cancer type is necessary. The early 
identification of mechanisms of tumor cell resistance is also important to change the treatment 
strategies or combine it with other methods. Finally, a better understanding of molecular, 
genetic and epigenetic factors involving in the pathogenesis of cancer are warranted. 
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